Conference Coverage
Ocrelizumab safety update: Encouraging rates of serious infection, malignancy
No new safety signals were seen in the latest update from studies and postmarketing surveillance of MS patients treated with ocrelizumab.
Conference Coverage
Interferon treatment does not increase stroke risk in MS
Pooled data from 17 trials, as well as postmarketing surveillance data, show no increase in stroke risk with interferon treatment in MS patients...
Conference Coverage
EVOLVE-MS-1 study: ALKS 8700 shows promise for RRMS
LOS ANGELES – ALKS 8700, a novel prodrug of monomethyl fumarate, looks promising as an oral, disease-modifying treatment for RRMS.
Conference Coverage
Interim Results Show Efficacy for a Novel MS Drug
LOS ANGELES—Preliminary results for annualized relapse rate and MRI parameters support ALKS 8700 (also known as BIIB098) as an oral treatment for...
Article
Deep Gray Matter Volume Loss May Drive Disability Worsening in MS
Deep gray matter volume loss drives disability accumulation in multiple sclerosis (MS), according to a multicenter, longitudinal study published...
Article
MRI May Reveal PML in Patients With Undetectable JCV
Patients with multiple sclerosis (MS) who are treated with natalizumab can have small progressive multifocal leukoencephalopathy (PML) lesions on...
Article
Siponimod May Benefit Patients With Secondary Progressive MS
Among patients with secondary progressive multiple sclerosis (MS), siponimod appears to decrease the risk of disability progression, according to...
Conference Coverage
MRI Techniques Could Help Distinguish Between MS and Migraine
STOWE, VT—Some patients with migraine receive an inappropriate diagnosis of multiple sclerosis (MS). The two disorders share certain clinical and...
Conference Coverage
MS drugs in Medicare Part D: Higher tiers, less coverage, more prior authorizations
LOS ANGELES – The 2007-2016 analysis includes 11 drugs falling under Medicare Part D.
Video
VIDEO: AAN MS guidelines aim to help clinicians weigh expanding drug choices
LOS ANGELES – A “dramatically different” landscape of treatment options allows better tailoring to patients, authors say.
Conference Coverage
Eating Fish May Be Associated With a Reduced Risk of MS
LOS ANGELES—Eating fish at least once per week or eating fish one to three times per month, in addition to taking daily fish oil...
News
Blood-brain barrier health may signal early loss of MS treatment response
A single dynamic contrast-enhanced MRI scan at 6 months was predictive in patients taking natalizumab or fingolimod.
News
Rare, serious alemtuzumab adverse events emerge
New reports reveal rare adverse events in the treatment of relapsing-remitting multiple sclerosis using alemtuzumab.
Video
Ari Green, MD
Dr. Green, Chief of the Division of Neuroinflammation and Glial Biology at the University of California, San Francisco, discusses the...
Conference Coverage
High Dose of Novel Compound Shows Promise for Relapsing-Remitting MS
SAN DIEGO—Patients with relapsing-remitting multiple sclerosis (MS) who received high doses of the novel human endogenous retrovirus-W antagonist...
Conference Coverage
What Is the Mechanism of Alemtuzumab-Induced Autoimmunity?
SAN DIEGO—The monoclonal antibody alemtuzumab can be an effective treatment for people living with multiple sclerosis (MS), but the agent is also...
Conference Coverage
Patients With MS May Not Receive Appropriate Medicines From Primary Care Doctors
SAN DIEGO—Patients with multiple sclerosis (MS) who are treated by primary care physicians are significantly less likely to receive disease-...
Conference Coverage
Multimedia
Question 1 of 5
